$ACT Company News What a week: Botox haze, merger

New Post Public Reply Private Reply Replies (0) Message Board

Dec 15, 2014 at 12:42 PM

$ACT Company News

What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Actavis, Allergan close to a deal 8:33 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Allergan, Actavis near cash-and-stock deal: WSJ 1:48 p.m. Nov. 16, 2014 - Andria Cheng
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Actavis sales surge, exceed forecasts 7:51 a.m. Nov. 5, 2014 - MarketWatch.com
Media, consumer-based company earnings to test stock rally 4:30 a.m. Nov. 2, 2014 - Wallace Witkowski
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015 9:27 a.m. Today - TheStreet.com
5 “Best of the Best” Stocks for 2015 5:11 a.m. Today - InvestorPlace.com
What Investors Can Learn From The Portfolios Of Fund Managers 5:47 a.m. Dec. 14, 2014 - Seeking Alpha
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog 3:20 p.m. Dec. 12, 2014 - Zacks.com
Judge orders Actavis to keep selling Alzheimer's drug 12:49 p.m. Dec. 12, 2014 - Seeking Alpha
bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog 4:45 p.m. Dec. 11, 2014 - Zacks.com
Mylan Among First to Launch Generic Celebrex - Analyst Blog 4:22 p.m. Dec. 11, 2014 - Zacks.com
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog 3:20 p.m. Dec. 11, 2014 - Zacks.com
Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog 3:30 p.m. Dec. 10, 2014 - Zacks.com
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog 2:50 p.m. Dec. 10, 2014 - Zacks.com
What a Generic Celebrex Means for Pfizer and for Actavis 9:57 a.m. Dec. 10, 2014 - 247WallSt.com
The Gurus to Follow Based on Sector - Part 2 3:20 p.m. Dec. 9, 2014 - GuruFocus.com
Merck to Buy Cubist for $8.4 Billion 9:46 p.m. Dec. 8, 2014 - The Wall Street Journal Interactive Edition
Google, Microsoft Dominate Mutual Funds, Apple Still Most Popular In Hedge Funds: Citigroup 8:13 p.m. Dec. 8, 2014 - Seeking Alpha
Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog 6:30 p.m. Dec. 8, 2014 - Zacks.com
Top Global Stocks: Jazz, Actavis In IBD's World List 5:39 p.m. Dec. 8, 2014 - Investors Business Daily
Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog 5:10 p.m. Dec. 8, 2014 - Zacks.com
Merck Acquiring Cubist, Focusing On Hospital Care 10:48 a.m. Dec. 8, 2014 - Investors Business Daily
Deals, Deals, Deals: What Made 2014 Such a Big Year for Mergers 6:10 a.m. Dec. 8, 2014 - TheStreet.com
Big Number: Deals Fuel Bond Boom 9:44 p.m. Dec. 7, 2014 - The Wall Street Journal Interactive Edition

Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF
Critical Alerts For Gold Fields, Actavis, Trina Solar Limited, Alcoa and Herbalife Released By InvestorsObserver 9:31 a.m. Nov. 19, 2014 - PR Newswire - PRF
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 10:32 a.m. Nov. 17, 2014 - PR Newswire - PRF
Valeant Comments On Allergan Announcement 9:29 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue 9:15 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer 8:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 6:45 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 6:30 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4:15 p.m. Oct. 31, 2014 - PR Newswire - PRF
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amgen's Board Gains Restaurateur Gibbs Amid Strategic Shift

A Heavyweight Joiner Shakes Up Amgen's Ranks You can almost feel the ground shake when Amgen, a tech giant in biotech, ropes in a high-profile namesake from outside its usual league. David W. Gibbs, the former CEO of Yum! Brands, is now staking his claim at Amgen as a member of its Board of Directors. Effective immediately, Gibbs isn’t just a filler; he's diving...

University of Phoenix Grads Gain High Praise from Managers

Forget the stereotypes that tag University of Phoenix as just another factory for diplomas. The latest survey results paint a picture of graduates who seem to be real go-getters in the workplace. We’ve got managers from all over singing the praises of these alums, with a whopping 96% ready to vouch for them stepping into bigger roles. Not just talk, folks, this is their...

Rethinking Your Social Security Timing Strategy

Janie Kelly Challenges Conventional Wisdom Janie Kelly, the brain behind Kelly Capital Partners, just dropped a truth bomb on when to start claiming Social Security benefits, wrapped in a HelloNation article that lays it all out sans fluff. Forget about hopping on the bandwagon and claiming at the earliest shot—this is a decision as personal as it gets. It's all about...

Landis+Gyr's Big Contract Victory: A Game Changer?

Diving into Landis+Gyr's Major Utility Win When news hits about a deal secured by Landis+Gyr Group AG, it rings a few bells across the utility landscape. These folks have brewed up a storm with a fresh contract that slots into their rapidly expanding portfolio of grid-savvy products. So, what’s the fuss about this latest agreement? A Groundbreaking Contract Now, this...

Webull Faces Investor Lawsuit: Compliance in Question

Webull's Run into Regulatory Fog Well, here we go—another tech company caught with its pants down over alleged ties with China. Webull Corporation (NASDAQ:BULL) is in the crosshairs of a class action lawsuit. Investors are sharpening their pitchforks, and you've got until December 7, 2026, to throw your hat in the ring as lead plaintiff. The Core of the Allegations...

Ouma Connect Streamlines Surrogacy Medical Clearance

A Game Changer for Surrogacy Agencies When we talk about innovation, we often focus on the flashiest tech in finance or the buzz of a scorching hot stock. But here's Ouma Health, shifting gears in a sector many traders don't blink at—surrogacy. They're unveiling Ouma Connect, a portal pulling back the curtain on medical clearances for gestational-carrier candidates....

Temu Partners with Recyclia to Drive EPR Compliance Boost

Temu and Recyclia: Building a Sustainable Marketplace Get this: Temu, the e-commerce giant you've heard trumpeting about affordable goods like some digital bazaar, is diving deeper into sustainability waters with a partner that knows a thing or two about waste. This time, they've linked up with Recyclia over in Spain. The duo's focus? Helping marketplace sellers meet the...

Key Sewer Line Damage Signs Homeowners Often Ignore

Spotting Trouble Beneath the Surface Now, when was the last time you eyeballed your home’s plumbing with more than a passing glance? Most folks don’t give their sewer lines two thoughts until something foul pops up. Plumbing expert Jessica Gerdeman from Heggemann, Inc. in Warrenton, Missouri, isn’t just blowing hot air when she points out the indicators of looming...

Ademi LLP Questions RRC Buyout Deal's Fairness

Unease Surrounds RRC's Potential Acquisition by EQT Let’s talk about a messy situation brewing with Range Resources Corporation (NYSE: RRC). The lawyers at Ademi LLP are poking around in the shadows of a proposed buyout by EQT Corporation, questioning whether the deal is legit—or if someone’s getting the short end of the stick. It’s all happening in a climate...

Nucor's Q3 2026 Earnings: Strong Growth Amid Steel Surge

Nucor's Solid Third Quarter Performance Nucor Corporation is flexing its muscles, reporting a robust third quarter for 2026. With net earnings hitting $1.32 billion and a diluted earnings per share of $5.80, the steel giant has shown it can more than hold its ground in a competitive market. Compare that to last quarter's $1.16 billion - we're seeing serious momentum....